Key facts
- Notable investors include Catalio Capital Management, Blackbird BioVentures.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Winnow Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Winnow Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Winnow Therapeutics
Operator of a biotechnology research company based in Boston, Massachusetts. The company specializes in advancing a new class of antibody-based therapies designed for the highly selective depletion of pathogenic B and T cell clones while preserving protective immunity, enabling medical professionals to target auto-reactive immune repertoires with unprecedented specificity.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2025
- Employees
- 3
- Ownership
- Privately Held (backing)
Winnow Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Winnow Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Winnow Therapeutics in its N-PORT filings yet. We sweep new filings monthly.